TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $TRML stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TOURMALINE BIO Hedge Fund Activity
We have seen 59 institutional investors add shares of TOURMALINE BIO stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 600,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $12,168,000
- BLUE OWL CAPITAL HOLDINGS LP removed 451,080 shares (-29.5%) from their portfolio in Q4 2024, for an estimated $9,147,902
- STATE STREET CORP added 388,213 shares (+94.2%) to their portfolio in Q4 2024, for an estimated $7,872,959
- POINT72 ASSET MANAGEMENT, L.P. removed 338,437 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,863,502
- JENNISON ASSOCIATES LLC removed 306,173 shares (-26.6%) from their portfolio in Q4 2024, for an estimated $6,209,188
- CITADEL ADVISORS LLC added 209,126 shares (+47.6%) to their portfolio in Q4 2024, for an estimated $4,241,075
- UBS GROUP AG added 177,385 shares (+1497.4%) to their portfolio in Q4 2024, for an estimated $3,597,367
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
